Therefore, our results highlight that TINAGL1 is a new profibrotic factor in the liver, even after cure with DAA-based therapy, and that targeting TINAGL1 may be an innovative strategy for the treatment of liver fibrosis, especially in the post-antiviral era. This evidence concerns the gene TINAGL1 and Hepatic fibrosis.